Expertise
The sectors we work in.
The functions we've run.
SVI's coverage is grounded in roughly twenty years of operator experience across pharma, biotech, medical device, diagnostics, and radiopharma — not secondary-source familiarity. The sectors and functions below are the ones where that experience is direct.
Therapeutic & technology areas
Biologics
Large-molecule therapeutics, biosimilar competitive dynamics, manufacturing complexity, and the commercial models built around them.
CNS
Challenging regulatory and clinical pathways, patient identification and diagnosis-to-treatment gaps, payer coverage and reimbursement complexity.
Rare & Orphan Diseases
Concentrated payer dynamics, KOL and patient-advocacy network structure, breakthrough designation, and the commercial realities of small addressable populations.
Medical Devices
Capital equipment and disposable revenue models, hospital purchasing and GPO dynamics, competitive intensity, and regulatory pathway commercial implications.
Diagnostics
Lab versus point-of-care economics, CPT code structure and reimbursement, ordering patterns, and the link between diagnostic positioning and therapeutic uptake.
Radiopharmaceuticals
Specialized manufacturing and distribution constraints, centers-of-excellence infrastructure, treatment site economics, and access barriers in a rapidly evolving segment.
Commercial Excellence
Sales force design and effectiveness, launch readiness, market access and reimbursement strategy, and the gap between commercial thesis and commercial execution.
Operational & AI Optimization
Workflow automation, AI-enabled process improvement, and the ROI and organizational readiness questions that determine whether efficiency claims hold at scale.
Functions the work draws on
Diligence questions don't stay inside one function. SVI's VP-level experience across these six areas means the analysis follows the question — not the org-chart boundary of a single practice area.
Strategy & Portfolio Management
Prioritization, resource allocation, and portfolio-level decision frameworks
Corporate Development
M&A and BD transaction assessment, deal structure, and post-close integration risk
Oncology R&D
Clinical and regulatory pathway assessment, pipeline credibility, and science-to-commercial translation
Alliance Management
Partnership structure, governance, and the commercial implications of co-development and co-promotion arrangements
International
Market entry, pricing architecture, and the reimbursement and distribution dynamics of ex-US markets
Commercial (Sales & Marketing)
Launch strategy, promotional mix, and the structural drivers of commercial performance
National coverage.
SVI works with deal teams nationally. Engagements are conducted the same way regardless of where the target is headquartered — direct operator review, not a local-office hand-off.
Deep familiarity with the major clusters.
In practice, most deal flow sits in a small number of geography-sector combinations: Boston–Cambridge biotech, the Bay Area, San Diego, the New Jersey–Philadelphia pharma corridor, Research Triangle, and the Minneapolis–Chicago medtech axis. These aren't locations on a coverage map — they're the clusters where the operating experience was built.